PortfoliosLab logo
AcelRx Pharmaceuticals, Inc. (ACRX)
Performance
Risk-Adjusted Performance
Dividends
Drawdowns
Volatility
Financials

Company Info

ISIN

US00444T1007

CUSIP

00444T100

IPO Date

Feb 14, 2011

Highlights

Market Cap

$14.58M

EPS (TTM)

-$2.75

Target Price

$4.63

Short %

3.75%

Short Ratio

4.56

Share Price Chart


Loading data...

Compare to other instruments

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.


Popular comparisons:
ACRX vs. SCHG
Popular comparisons:

Performance

Performance Chart

The chart shows the growth of an initial investment of $10,000 in AcelRx Pharmaceuticals, Inc., comparing it to the performance of the S&P 500 index or another benchmark. All prices have been adjusted for splits and dividends.


ACRX (AcelRx Pharmaceuticals, Inc.)
Benchmark (^GSPC)

Returns By Period


ACRX

YTD

N/A

1M

N/A

6M

N/A

1Y

N/A

5Y*

N/A

10Y*

N/A

^GSPC (Benchmark)

YTD

-4.26%

1M

11.24%

6M

-5.02%

1Y

8.55%

5Y*

14.02%

10Y*

10.31%

*Annualized

Monthly Returns

The table below presents the monthly returns of ACRX, with color gradation from worst to best to easily spot seasonal factors. Returns are adjusted for dividends.


JanFebMarAprMayJunJulAugSepOctNovDecTotal
202441.50%30.77%-17.08%53.43%
2023-11.50%-29.00%-53.66%1.82%48.66%11.45%-7.21%0.00%-43.69%-10.34%41.35%-0.00%-67.48%
2022-14.21%-6.05%-36.77%-12.54%-9.05%7.57%-15.68%43.20%-29.15%-36.84%-9.47%-5.44%-79.83%
202177.42%-14.55%-9.57%-23.53%6.92%-0.72%-14.49%-5.08%-8.93%-13.73%-25.93%-14.05%-54.82%
2020-19.43%-22.35%-10.61%36.44%-13.66%-12.95%-9.92%14.68%13.60%20.42%-12.28%-17.33%-41.23%
20196.49%36.59%3.57%11.21%-33.07%-2.32%3.16%-10.73%-5.58%-9.09%-7.00%13.44%-8.66%
2018-6.17%-5.26%16.67%14.29%41.67%-0.74%-17.04%10.71%24.19%7.53%-18.60%-31.45%14.07%
20171.92%15.09%3.28%-17.46%-3.85%-14.00%81.40%-15.38%39.39%-58.70%14.47%-6.90%-22.12%
2016-6.23%2.77%-16.98%9.74%2.37%-22.25%34.94%-13.22%23.49%-28.02%10.71%-16.13%-32.47%
2015-0.45%32.24%-56.43%3.37%-12.28%21.14%-2.83%3.88%-28.74%29.18%45.18%-32.69%-42.79%
20140.97%0.09%5.07%-9.91%-14.97%11.41%-32.10%2.73%-23.22%20.77%0.45%-94.95%-97.02%

Risk-Adjusted Performance

Risk-Adjusted Performance Indicators

The charts below present risk-adjusted performance metrics for AcelRx Pharmaceuticals, Inc. (ACRX) and compare them to a chosen benchmark (^GSPC). These indicators evaluate an investment's returns against its associated risks.


There is not enough data available to calculate the Sharpe ratio for AcelRx Pharmaceuticals, Inc.. We calculate this metric based on the past 12 months of trading data. Please check back later for updated information.


Rolling 12-month Sharpe Ratio
ACRX (AcelRx Pharmaceuticals, Inc.)
Benchmark (^GSPC)

Dividends

Dividend History


AcelRx Pharmaceuticals, Inc. doesn't pay dividends

Drawdowns

Drawdowns Chart

The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.


ACRX (AcelRx Pharmaceuticals, Inc.)
Benchmark (^GSPC)

Worst Drawdowns

The table below displays the maximum drawdowns of the AcelRx Pharmaceuticals, Inc.. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.

The maximum drawdown for the AcelRx Pharmaceuticals, Inc. was 99.99%, occurring on Nov 10, 2023. The portfolio has not yet recovered.


Depth

Start

To Bottom

Bottom

To Recover

End

Total

-99.99%Jul 23, 20132596Nov 10, 2023
-60%Jun 1, 2011135Dec 30, 2011218Nov 26, 2012353
-33.4%Nov 27, 20128Dec 6, 20127Dec 17, 201215
-31.05%Feb 15, 201145Apr 19, 201127May 27, 201172
-21.97%Feb 14, 201323Mar 19, 201316Apr 11, 201339

Volatility

Volatility Chart

The current AcelRx Pharmaceuticals, Inc. volatility is 34.32%, representing the average percentage change in the investments's value, either up or down over the past month. The chart below shows the rolling one-month volatility.


ACRX (AcelRx Pharmaceuticals, Inc.)
Benchmark (^GSPC)

Financials

Financial Performance

The chart below illustrates the trends in the financial health of AcelRx Pharmaceuticals, Inc. over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.


Annual
Quarterly

0.0

Earnings Per Share

The chart presents the Earnings Per Share (EPS) performance of AcelRx Pharmaceuticals, Inc., comparing actual results with analytics estimates. The company has exceeded analyst expectations for EPS in the past quarter, achieving a 71.4% positive surprise.


-4.00-3.00-2.00-1.000.00AprilJulyOctober2021AprilJulyOctober2022AprilJulyOctober2023AprilJuly
-0.08
-0.28
Actual
Estimate

Valuation

The Valuation section provides an overview of how AcelRx Pharmaceuticals, Inc. is priced in the market compared to other companies in the Drug Manufacturers - Specialty & Generic industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.


PEG Ratio

The chart shows the Price/Earnings to Growth (PEG) ratio for ACRX compared to other companies in the Drug Manufacturers - Specialty & Generic industry. ACRX currently has a PEG ratio of 0.0. This PEG ratio is low compared to industry peers, which could indicate the stock is undervalued relative to its expected growth.

PS Ratio

This chart shows the Price-to-Sales (P/S) ratio for ACRX relative to other companies in the Drug Manufacturers - Specialty & Generic industry. Currently, ACRX has a P/S ratio of 39.4. This P/S ratio is high relative to other companies in the industry. It could mean the stock is overvalued, or that investors expect strong future growth and profitability.

PB Ratio

The chart illustrates the Price-to-Book (P/B) ratio for ACRX in comparison with other companies in the Drug Manufacturers - Specialty & Generic industry. Currently, ACRX has a P/B value of 0.7. This P/B ratio is in line with the industry average, suggesting the stock is valued fairly in relation to its book value.

Income Statement



TTM
Revenue

Total Revenue

Cost Of Revenue

Gross Profit

Operating Expenses

Selling, General & Admin Expenses

R&D Expenses

Depreciation And Amortization

Total Operating Expenses

Income

Income Before Tax

Operating Income

EBITDA

EBIT

Earnings From Continuing Operations

Net Income

Income Tax Expense

Other Non-Operating Income (Expenses)

Extraordinary Items

Discontinued Operations

Effect Of Accounting Charges

Non Recurring

Minority Interest

Other Items

Interest Income

Interest Expense

Net Interest Income

Values in undefined except per share items